Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Condition: Atrial Fibrillation Interventions: Drug: Phenprocoumon; Drug: Apixaban; Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Edoxaban Sponsors: Bayer; Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials